Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6WO5I
|
|||
| Drug Name |
Frexalimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Phase 2 | [1] | |
| Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0; ICD-9: 710.2] | Phase 2 | [2] | ||
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [3] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04572841) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sj?gren's Syndrome (pSjS). U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT05039840) Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.